After years of controversy, a therapy based on human embryonic stem cells is finally being tested in humans. The treatment holds out hope to paralyzed people, but at how great a risk?
Antonio RegaladoFollow @twitterapi
Senior Editor, Business
I am the business editor of MIT Technology Review. I look for stories about how technology is changing business. Before joining MIT Technology Review in July 2011, I lived in São Paulo, Brazil, where I wrote about science, technology, and politics in Latin America for Science and other publications. From 2000 to 2009, I was the science reporter at the Wall Street Journal and later a foreign correspondent.
Antonio Regalado's Stories
California-based Amyris has used breakthroughs in synthetic biology to reinvent biofuels. To turn its technology into an industrial process, it has headed to the land of sugar: Brazil.
Will the frenzy of gene patenting drive innovation-or stifle medical advances?
DNA-based PCs? Doubtful. But DNA might do some computing-while assembling nanostructures.
The Human Genome Project piles up Everests of data. But getting new drugs out of it will require sophisticated software for sniffing out patterns--one of the most crucial tasks of the hot field known as bioinformatics.
Reviled in the '80s and forgotten in the '90s, the artificial heart is back and beating. TR readers get a rare glimpse inside the company that's developing it.
Capturing the human embronic stem cell might change the face of medicine. But to get there, a small band of researchers and biotech firms must endure a federal funding ban and ethical controversy.
The first one has turned up masses of genetic information. But its real payoff will come from mapping interactions among the cell's workhorses: the proteins.